Background
==========

*Acinetobacter baumannii* is an important nosocomial pathogen that causes pneumonia, bacteremia, meningitis, urinary tract infections, and other inflammation-related diseases \[[@b1-medscimonit-22-1801]--[@b5-medscimonit-22-1801]\]. It is difficult to treat *A. baumannii* infections owing to the occurrence of drug resistance and the ability of the pathogen to propagate worldwide. This infection contributes to the high mortality rates of in-patients (23%) and patients in the intensive care unit (ICU; 43%) and represents a major clinical issue \[[@b6-medscimonit-22-1801]\].

Currently, *A. baumannii* drug resistance is believed to be related to specific antibiotic hydrolases produced by *A. baumannii*; these hydrolases could alter drug-binding proteins, bacterial structure, and the number of porins, and could increase the activity of efflux pumps \[[@b7-medscimonit-22-1801]--[@b10-medscimonit-22-1801]\]. Furthermore, *A. baumannii* can live in the form of a biofilm in the external environment, resistant to disinfectants, ultraviolet light, and host immune defenses. This biofilm increases the difficulty of preventing and controlling *A. baumannii* infections \[[@b11-medscimonit-22-1801]\].

A previous review illustrated several specific genes, including *csuA*/*BABCDE*, *ompA*, *abaI*, and *pgaABCD*, that may determine the biofilm formation of *A. baumannii* \[[@b12-medscimonit-22-1801]\]. Furthermore, alternative protein complexes involved in biofilm formation are assembled in different *A. baumannii* strains and are highly correlated with the uneven distributions of different biofilm-associated protein (BAP) types \[[@b13-medscimonit-22-1801]\]. The relationship between biofilm-related genes and *A. baumannii* biofilm formation was described in previous studies \[[@b14-medscimonit-22-1801]--[@b18-medscimonit-22-1801]\]. For example, Breij et al. suggested that there may be an association between the *csuA*/*BABCDE* gene and *A. baumannii* biofilm formation on abiotic surfaces \[[@b14-medscimonit-22-1801]\]. Furthermore, *ompA* can be integrated into host epithelial cell and mitochondrial membranes and induce cell death, or participate in the extrusion of compounds from the periplasmic space through the outer membrane and couple with inner membrane efflux systems, which may be associated with drug resistance in *A. baumannii* infections \[[@b16-medscimonit-22-1801]\]. The autoinducer synthase abaI is necessary for biofilm formation and plays an important role in the late stages of biofilm maturation \[[@b15-medscimonit-22-1801],[@b17-medscimonit-22-1801]\]. Moreover, the ability of *A. baumannii* to adhere to epithelial cells may be enhanced by *bla-PER1* \[[@b18-medscimonit-22-1801]\]. Currently, although several potential relationships have been detected in previous studies, the relationship between biofilm-related genes, biofilm formation, and drug resistance of *A. baumannii* in China remains unclear. Furthermore, the correlations between antibiotic resistance and the four *A. baumannii* genes related to biofilm formation are still controversial. Therefore, we conducted a retrospective study to explore the potential association between the four biofilm-related genes and drug resistance by detecting *csuA/BABCDE*, *ompA*, *abaI*, and *bla-PER1* in *A. baumannii* isolates from clinical specimens.

Material and Methods
====================

Ethics statement
----------------

This study was approved by the Ethics Committee of Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China (2012001). The purpose and procedures of the study were carefully explained to all participants and written informed consent was obtained from all participants. All the clinical isolates analyzed in this work were collected as part of routine medical care. All the data analyzed in this work had already been anonymized before analysis.

Patients and inclusion criteria
-------------------------------

One hundred twenty-two patients with lower respiratory tract infection by *A. baumannii* were enrolled in this study after hospitalization in various departments at Fujian Longyan First Hospital between January 2013 and September 2014. The exclusion criteria included immune deficiency and previous use of hormone therapy. Patients' primary disease, aggressive treatment, clinical symptoms, temperature, white blood cell count (WBC), and X-ray examination results were recorded by investigators. The patients had clinical symptoms that included cough with purulent sputum or increasing sputum volume, moist crackles, or lung X-ray examination with pulmonary infiltrates or with fuzzy and increased lung markings. Furthermore, we also carried out laboratory tests, imaging examinations, and microbiological examinations. Using "Diagnostic Criteria for Hospital Infections" as the basis for diagnosis, patients were eligible for inclusion in the study if the following criteria were met: (1) *A. baumannii* was detected from two consecutive sputum cultures, and (2) *A. baumannii* ≥10^5^ CFU/mL was detected from lower respiratory tract secretions that were collected by fiber optic bronchoscopy or artificial airways.

Source of bacterial strains
---------------------------

*A. baumannii* bacteria were obtained from sputum specimens from the first deep lung expectorant of patients after waking and rinsing their mouths using normal saline. Strains were detected using a BD Phoenix100 automated microbial identification system (Becton Dickinson and Company, NJ, USA). The reference strains *Escherichia coli* ATCC25922 and *Pseudomonas aeruginosa* ATCC27853 were used as controls (OXOID Company, Basingstoke, England).

Genomic DNA extraction
----------------------

A pure culture colony was picked and placed in a 1.0 mL centrifuge tube. *A. baumannii* genomic DNA was extracted using a TIANGEN bacterial genomic DNA extraction kit (TIANGEN Biotech Company, Beijing, China) according to the manufacturer's instructions. DNA was stored at −20°C until use.

Gene detection
--------------

Target genes were detected using polymerase chain reaction (PCR). The various target gene primer sequences \[[@b16-medscimonit-22-1801]--[@b18-medscimonit-22-1801]\] and product lengths are shown in [Table 1](#t1-medscimonit-22-1801){ref-type="table"}. Each biofilm-associated gene amplification reaction included 1 μL each of P1 and P2 primers (10 nM), 3 μL of 200 mM dNTPs, 3 μL of buffer containing 15 mM MgCl~2~, 2 μL DNA template, 5 U/μL Taq enzyme (1 μL), and 19 μL of double-distilled H~2~O for a total reaction volume of 30 μL.

The PCR thermal cycling parameters for *abaI* and *csuE* were an initial denaturation at 95°C for 10 minutes; followed by 35 cycles of 95°C for 30 seconds, 63°C for 30 seconds, and 72°C for 1 minute; and a final extension at 72°C for 10 minutes. The PCR thermal cycling parameters for *ompA* and *bla-PER1* were an initial denaturation at 95°C for 10 minutes; followed by 35 cycles of 95°C for 30 seconds, 52°C for 30 seconds, and 72°C for 1 minute; and a final extension at 72°C for 10 minutes.

By comparing the resulting bands and a DNA base pair marker following 2% agarose gel electrophoresis, products that showed the expected molecular weight were regarded as positive \[[@b19-medscimonit-22-1801]\].

Drug sensitivity test
---------------------

The microdilution quantitative minimum inhibitory concentration (MIC) method was used to determine the antimicrobial susceptibility of each strain. According to the US CLSI2013 susceptibility criteria, susceptibility paper from the OXOID Company was applied for the assessment of drug sensitivity. Multidrug resistance was defined as isolates showing drug resistance to three or more of the following five classes of antibiotics: cephalosporins, carbapenems, compounds of β-lactamase inhibitors, fluoroquinolones, and aminoglycosides. Pan-drug resistance was defined as isolates showing drug resistance to all classes excluding polymyxin.

Statistical analyses
--------------------

Baseline data are presented as the mean ± standard deviation and rate. Comparisons between positive and negative genes were made using *t*-tests and χ^2^ tests. First, we used univariate logistic regression to determine any potential confounders. Furthermore, drug resistance was investigated by logistic regression for analyzing the odds ratio after adjustment for gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes. Statistical analyses were performed with two-sided tests. Differences with *P*-values of less than 0.05 were considered statistically significant. The data were analyzed using Statistical Package for the Social Sciences version 19.0 (SPSS 19.0).

Results
=======

Baseline characteristics
------------------------

As shown in [Table 2](#t2-medscimonit-22-1801){ref-type="table"}, there were 102 men and 20 women enrolled in this study. The mean age of the enrolled patients was 64±22 years. Additionally, 54.9% (67/122) of *A. baumannii*-infected patients were admitted to the ICU, and 33 patients (27%, 33/122) had chronic obstructive pulmonary disease (COPD). The long-term invasive treatments to which patients were exposed included tracheotomy, mechanical ventilation, intravenous indwelling catheterization, retention catheterization, and sputum suction. The proportion of infections associated with tracheotomy, mechanical ventilation, and sputum suction were 74.07% (40/54), 71.67% (43/60), and 46.67% (28/60), respectively. Patients had cough, sputum, pulmonary moist rales, imaging changes, and other clinical symptoms.

Biofilm-related gene analysis
-----------------------------

In the 122 sputum specimens, the detection rates of *abaI* and *csuE* were both 59.8%, and those of *ompA* and *bla-PER1* were 100% and 0%, respectively. The results of our analysis of biofilm-related genes are shown in [Table 3](#t3-medscimonit-22-1801){ref-type="table"}.

Antibiotic resistance
---------------------

Resistance rates are shown in [Table 4](#t4-medscimonit-22-1801){ref-type="table"}. *abaI*- and *csuE*-positive and negative specimens showed statistically significant differences in the rates of resistance to amikacin, ampicillin/sulbactam, cefepime, cefoperazone/sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin/tazobactam, tetracycline, cotrimoxazole (SMZco), and levofloxacin (*P*\<0.001). Moreover, there was a statistically significant difference between *abaI*-positive and *abaI*-negative groups (*P*\<0.05) whereas no statistically significant difference was observed between *csuE* positive and *csuE*-negative groups (*P*\>0.05). The odds ratios for the association between specific drug resistance rates and positivity for the *abaI* and *csuE* genes are presented in [Table 5](#t5-medscimonit-22-1801){ref-type="table"}. Overall, we noted that *abaI* and *csuE* positivity were associated with a statistically significant impact on amikacin, ampicillin, cefepime, sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin, tetracycline, SMZco, and levofloxacin resistance after adjustment for gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes.

Discussion
==========

*A. baumannii* is an opportunistic pathogen that can colonize the skin, conjunctiva, oral cavities, respiratory tract, gastrointestinal tract, and urinary tract \[[@b20-medscimonit-22-1801]\]. Furthermore, *A. baumannii* infections frequently occur in the intensive care unit and respiratory department. These patients are often in critical condition, have lower immune function, exhibit poor nutritional status, and may also have diabetes, cancer, chronic wasting disease, and other diseases of the brain, heart, kidneys, or lungs. Thus, these patients often have decreased resistance and increased susceptibility to infection \[[@b21-medscimonit-22-1801]\]. The symptoms caused by lower respiratory tract infections of *A. baumannii* include cough, sputum, and pulmonary moist rales. In addition, patients often exhibit distinct x-ray images, such as multiple scattered small patchy shadows, large patchy shadows, cystic lung or cylindrical bronchiectasis, and pleural effusions, which lack clinical specificity. Therefore, microbiological examinations are needed to confirm *A. baumannii* infection as soon as possible in order to maximize recovery rates. The findings of our study suggested that *abaI*- and *csuE*-positive strains were associated with 14 types of antimicrobial resistance, as shown in [Table 4](#t4-medscimonit-22-1801){ref-type="table"}. Furthermore, after adjusting for gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes, *abaI* and *csuE* were associated with significant effects on amikacin, ampicillin, cefepime, sulbactam, cefotaxime, ceftazidime, ciprofloxacin, gentamicin, imipenem, meropenem, piperacillin, tetracycline, SMZco, and levofloxacin resistance.

Bacterial biofilms are associated with problems in the prevention and treatment of *A. baumannii* infection \[[@b11-medscimonit-22-1801]\]. Biofilms irreversibly adhere in the host's tissues or on abiotic surfaces and are supported by polymer matrices that are secreted by the microorganisms themselves, facilitating the formation of bacterial communities \[[@b22-medscimonit-22-1801]\]. This viscous matrix can separate bacteria from harmful external factors, thereby increasing the resistance of the microbial community \[[@b22-medscimonit-22-1801]\]. These observations may be explained as follows: (1) permeation limitation: bacteria at high density in biofilms can produce an extracellular matrix that impedes antibiotic penetration; (2) nutrition restrictions: bacteria in biofilms are maintained in a state of low metabolism and a slow growth rate, making them less sensitive to outside stimuli, such as antibiotics; (3) phenotype inference: biological membranes select or induce strains with resistant phenotypes and increase the number of antibiotic resistance genes and the expression of resistance efflux pumps, leading to drug resistance; (4) immune suppression: *A. baumannii* biofilms are a natural physical barrier that limit immune-mediated killing of the organism; and (5) quorum sensing: following an increase in the number of *A. baumannii*, some bacteria are detached from the surface of the biofilm by quorum sensing and are transformed into a planktonic growth state, allowing bacteria to adhere to appropriate media and leading to the spread of infection and relapse \[[@b14-medscimonit-22-1801],[@b23-medscimonit-22-1801],[@b24-medscimonit-22-1801]\].

The clinical signs of *A. baumannii*-infected patients and the possible factors that influence drug resistance were also examined in this study. The reasons for this include permeation limitation, nutrition restrictions, phenotype inference, immune suppression, and quorum sensing, as discussed above. Therefore, the following prevention and treatment methods are recommended: (1) regular disinfection of wards and medical containers should be conducted; (2) medical personnel should practice hand hygiene; (3) the duration of mechanical ventilation and body catheterization should be shortened; and (4) early diagnosis and drug resistance testing should be a priority in order to enhance preventive measures.

Our study had several limitations. First, stratified analyses based on potential confounders were not conducted due to the insufficient sample size. Second, patients with different disease statuses and admitted to different clinical centers were enrolled in this study, which may have affected the observed results.

Thus, an improved understanding of the association between biofilm formation and resistance mechanisms is needed because once drug-resistant strains form biofilms, treatment becomes extremely difficult. *AbaI*- and *csuE*-positive strains were the most resistant to the 14 types of antimicrobials; therefore, detecting these genes can guide antibiotic use in *A. baumannii*-infected patients. Further studies are needed to determine whether strains carrying *abaI* and *csuE* are associated with biofilm formation.

Conclusions
===========

*A. baumannii* infected patients were most commonly admitted to intensive care units and the respiratory department, and the patients frequently had chronic obstructive pulmonary disease. The patients infected with *A. baumannii*-induced lower respiratory tract infections lacked clinical specificity. The majority of the *A. baumannii* isolates from mainland China were susceptible to polymyxin E. *AbaI*- and *csuE*-positive strains were associated with higher incidence of 14 types of antimicrobial resistance. Detecting the *abaI* and *csuE* genes can provide important information for clinical treatment by certain antibiotics. An improved understanding of the association between biofilm formation and resistance mechanisms is needed, and some preventive measures such as shortening the duration of mechanical ventilation should be instituted to avoid biofilm formation.
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###### 

Target gene PCR primer sequences and product lengths.

  Gene                                            Primer sequence (5′-3′)           Product length
  ------------ ---------------------------------- --------------------------------- ----------------
  *abaI*       P1                                 GTACAGTCGACGTATTTGTTGAATATTTGGG   382 bp
  P2           CGTACGTCTAGAGTAATGAGTTGTTTTGCGCC                                     
  *csuE*       P1                                 ATGCATGTTCTCTGGACTGATGTTGAC       976 bp
  P2           CGACTTGTACCGTGACCGTATCTTGATAAG                                       
  *ompA*       P1                                 CAATTGTTATCTCTGGAG                966 bp
  P2           ACCTTGAGTAGACAAACGA                                                  
  *bla-PER1*   P1                                 ATGAATGTCATTATAAAAGC              978 bp
  P2           AATTTGGGCTTAGGGCAGAA                                                 

###### 

Baseline characteristics of patients with *A. baumannii* infections.

                                              Mean/number   Range/rate
  ------------------------------------------- ------------- ---------------
  Gender (male)                               102           83.6
  Mean age                                    64            (1, 98)
  Length of hospital stay (day)               16.5          (4, 95)
  Body temperature (admission)                37.15         (35.0, 39.6)
  Body temperature (return samples)           37.70         (36.0, 39.1)
  Body temperature (1 day after infection)    37.40         (35.5, 40.2)
  Body temperature (7 days after treatment)   37.10         (36.0, 39.1)
  WBC (admission)                             11.2          (2.86, 32.14)
  WBC (return samples)                        12.46         (2.77, 29.81)
  WBC (1 day after infection)                 12.21         (2.35, 30.81)
  WBC (7 days after treatment)                11.25         (4.94, 26.05)
  Intensive Care Unit                         67            54.9%
  Respiratory Department                      19            15.6
  COPD                                        33            27.0%
  Cardiovascular disease                      25            20.5%
  Cerebral trauma                             14            11.5%
  Diabetes                                    19            15.6%
  Hypertension                                26            21.3%
  Ventilator                                  43/60         71.67%
  Tracheotomy                                 40/54         74.07%
  Urine tube                                  14/42         33.33%
  Venous catheterization                      7/29          24.14%
  Sputum suction                              28/60         46.67%
  Fever                                       57            46.72%
  Small shape shadow                          70            57.38
  Large shape shadow                          40            32.79

###### 

Biofilm-related gene expression.

  Gene         Positive   Positive rate (%)
  ------------ ---------- -------------------
  *abaI*       73         59.8
  *csuE*       73         59.8
  *ompA*       122        100.0
  *bla-PER1*   0          0.0

###### 

Differences in *abaI* and *csuE* positivity and responses to antimicrobial agents.

  Drug                      DRR (n%)   *abaI* DRR (n%)   *csuE* DRR (n%)                                
  ------------------------- ---------- ----------------- ----------------- ------------ ------- ------- ------------
  Amikacin                  53.3       80.82             12.24             \<0.001      78.08   16.33   \<0.001
  Ampicillin/Sulbactam      65.6       97.26             18.37             \<0.001      94.52   22.45   \<0.001
  Cefepime                  65.6       98.63             16.32             \<0.001      93.15   24.49   \<0.001
  Cefoperazone/Sulbactam    28.7       45.20             4.08              \<0.001      40.09   10.20   \<0.001
  Cefotaxime                63.9       97.26             14.29             \<0.001      93.15   10.20   \<0.001
  Ceftazidime               63.9       97.26             14.29             \<0.001      93.15   10.20   \<0.001
  Ciprofloxacin             67.2       97.26             22.45             \<0.001      94.52   26.53   \<0.001
  polymyxin E               0.0        0.00              0.00              \>0.05^\*^   0.00    0.00    \>0.05^\*^
  Gentamicin                64.8       97.26             16.33             \<0.001      93.15   22.45   \<0.001
  Imipenem                  60.7       95.89             8.16              \<0.001      91.78   14.28   \<0.001
  Meropenem                 59.8       94.52             8.16              \<0.001      91.78   12.24   \<0.001
  Piperacillin/Tazobactam   61.5       95.89             18.18             \<0.001      91.78   16.33   \<0.001
  Tetracycline              70.5       95.89             32.65             \<0.001      94.52   34.69   \<0.001
  SMZco                     65.6       94.52             22.45             \<0.001      91.78   26.53   \<0.001
  Levofloxacin              63.1       95.89             14.26             \<0.001      93.15   18.37   \<0.001

DRR -- drug resistance rate.

###### 

Associations between specific drug resistance rates and *abaI* and *csuE* positivity after adjustment for various factors.

  Drug            Adjusted odds ratio for *abaI*   95% CI for *abaI*   P value for *abaI*   Adjusted odds ratio for *csuE*   95% CI for *csuE*   P value for *csuE*
  --------------- -------------------------------- ------------------- -------------------- -------------------------------- ------------------- --------------------
  Amikacin        41.57                            14.03--123.17       \<0.001              15.84                            5.82--43.15         \<0.001
  Ampicillin      741.65                           38.33--14349.88     \<0.001              89.71                            17.81--451.83       \<0.001
  Cefepime        3466.57                          44.60--269445.75    \<0.001              132.66                           15.57--1130.04      \<0.001
  Sulbactam       102.99                           11.81--898.31       \<0.001              20.06                            5.07--79.28         \<0.001
  Cefotaxime      167.96                           14.72--1916.05      \<0.001              76.66                            10.07--583.30       \<0.001
  Ceftazidime     181.58                           31.77--1037.97      \<0.001              142.71                           21.51--946.93       \<0.001
  Ciprofloxacin   107.67                           19.29--600.89       \<0.001              81.78                            15.72--425.44       \<0.001
  Gentamicin      224.19                           33.47--1501.67      \<0.001              193.38                           20.88--1791.48      \<0.001
  Imipenem        272.09                           46.87--1579.63      \<0.001              316.75                           30.33--3308.09      \<0.001
  Meropenem       269.92                           46.49--1567.26      \<0.001              284.59                           29.22--2772.08      \<0.001
  Piperacillin    511.61                           49.60--5276.73      \<0.001              191.58                           22.62--1622.41      \<0.001
  Tetracycline    31.35                            8.15--120.54        \<0.001              32.87                            8.57--126.02        \<0.001
  SMZco           60.51                            15.34--238.79       \<0.001              35.65                            10.07--126.24       \<0.001
  Levofloxacin    267.31                           34.07--2097.17      \<0.001              138.57                           22.46--855.06       \<0.001

CI -- confidence interval. Adjusted: gender, mean age, department, ventilator, tracheotomy, cardiovascular disease, and diabetes.
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